Aura Biosciences, Inc. (AURA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-16

Key Insights

The reporting person, Conor Kilroy, sold 11,738 shares of Aura Biosciences, Inc. (AURA) common stock at a weighted average price of $7.02 per share. This appears to be an automatic sale to cover tax withholding obligations related to the vesting of restricted stock units.
The sale represents a small portion (5.4%) of Kilroy's total beneficial ownership of 217,835 shares, suggesting this was a routine transaction and not a significant change in his position.
Insider selling can sometimes signal lack of confidence in the company's future prospects, but the context and size of the transaction suggest this was likely a standard practice rather than a concerning signal.

Current Report Filed: 2026-03-30

Key Insights

Aura Biosciences announced its Q4 and full-year 2025 financial results, highlighting the continued progress of its research and development programs.
The company updated its corporate presentation, which is likely to be used in meetings with investors, analysts, and others to discuss the company's latest developments.
Aura Biosciences provided a cautionary note regarding forward-looking statements, emphasizing the risks and uncertainties associated with its clinical trials and regulatory approvals.

Annual Report Filed: 2026-03-30

Key Insights

Aura Biosciences, Inc. is a late-stage biotechnology company focused on developing novel therapies for ocular and oncologic indications. The company has made progress on its clinical pipeline, including entering into a collaboration agreement with Dr. John Schiller.
Aura has raised additional capital through follow-on offerings and at-the-market offerings, which should provide funding to support its ongoing research and development activities.
The company has entered into various licensing and supply agreements, including with LI-COR, Inc., which provide access to key technologies and support its product development efforts.

Insider Trading Filed: 2026-01-20

Key Insights

The reporting person, Elisabet de los Pinos, is the President and Chief Executive Officer of Aura Biosciences, Inc. and has significant beneficial ownership in the company.
The reporting person sold 16,928 shares of common stock at a weighted average price of $4.86 to cover tax withholding obligations related to the vesting of restricted stock units.
The reporting person also holds an indirect beneficial ownership of 127,763 shares of common stock through the Elisabet de los Pinos Revocable Trust.

Insider Trading Filed: 2026-01-20

Key Insights

The reporting person, Amy Elazzouzi, who is the Senior Vice President of Finance at Aura Biosciences, Inc., sold 1,581 shares of the company's common stock at $4.86 per share.
The sale was to cover tax withholding obligations in connection with the vesting of restricted stock units, and was not at the discretion of the reporting person.
The reporting person still holds 84,081 shares of the company's common stock, indicating they maintain a significant ownership stake.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.